Horizon Pharma PLC Company Profile (NASDAQ:HZNP)

About Horizon Pharma PLC (NASDAQ:HZNP)

Horizon Pharma PLC logoHorizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:HZNP
  • CUSIP: 44047T10
  • Web: www.horizonpharma.com
Capitalization:
  • Market Cap: $2.00436 billion
  • Outstanding Shares: 163,354,000
Average Prices:
  • 50 Day Moving Avg: $12.81
  • 200 Day Moving Avg: $12.94
  • 52 Week Range: $9.45 - $21.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 10.62
  • P/E Growth: 0.89
Sales & Book Value:
  • Annual Revenue: $1.03 billion
  • Price / Sales: 1.95
  • Book Value: $6.30 per share
  • Price / Book: 1.96
Profitability:
  • EBIDTA: ($46,520,000.00)
  • Net Margins: -42.40%
  • Return on Equity: 22.85%
  • Return on Assets: 6.86%
Debt:
  • Debt-to-Equity Ratio: 1.83%
  • Current Ratio: 1.61%
  • Quick Ratio: 1.46%
Misc:
  • Average Volume: 3.84 million shs.
  • Beta: 1.44
  • Short Ratio: 5.78
 

Frequently Asked Questions for Horizon Pharma PLC (NASDAQ:HZNP)

What is Horizon Pharma PLC's stock symbol?

Horizon Pharma PLC trades on the NASDAQ under the ticker symbol "HZNP."

How will Horizon Pharma PLC's stock buyback program work?

Horizon Pharma PLC declared that its board has approved a share buyback program on Sunday, June 4th 2017, which authorizes the company to buyback 1,000% of shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company's board of directors believes its stock is undervalued.

How were Horizon Pharma PLC's earnings last quarter?

Horizon Pharma PLC (NASDAQ:HZNP) released its quarterly earnings data on Monday, August, 7th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.29. The company had revenue of $289.51 million for the quarter, compared to analysts' expectations of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The firm's revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.56 EPS. View Horizon Pharma PLC's Earnings History.

When will Horizon Pharma PLC make its next earnings announcement?

Horizon Pharma PLC is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Horizon Pharma PLC.

Where is Horizon Pharma PLC's stock going? Where will Horizon Pharma PLC's stock price be in 2017?

11 equities research analysts have issued 1-year price targets for Horizon Pharma PLC's stock. Their forecasts range from $12.00 to $30.00. On average, they anticipate Horizon Pharma PLC's stock price to reach $18.91 in the next twelve months. View Analyst Ratings for Horizon Pharma PLC.

What are analysts saying about Horizon Pharma PLC stock?

Here are some recent quotes from research analysts about Horizon Pharma PLC stock:

  • 1. Cantor Fitzgerald analysts commented, "We are maintaining our Overweight rating and $17, 12 month PT for HZNP shares, but lowering our 2017 and 2018 EPS estimates because we have taken out some sales for the Raptor franchise now that Horizon has completed the sale of its EU marketing rights to Chiesi (Not Covered). We continue to expect Krystexxa sales to be impacted by the 340b program in 4Q17, which could prove conservative. Please see our note for details Potential HHS Delay Could Be Positive for HZNP’s Krystexxa Sales This Year. We expect orphan drug sales to increase 50% YOY which is in line with Horizon’s guidance, and rheumatology sales to increase 37% YOY, which is also roughly in line with Horizon’s guidance. Valuation. We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $17." (9/11/2017)
  • 2. According to Zacks Investment Research, "Horizon’s second-quarter results were impressive with the company beating on both the top and bottom line estimates. Moreover, the increase in sales guidance for 2017 was encouraging as well. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. Moreover, in Jun 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in the Europe, the Middle East and Africa regions to Chiesi Farmaceutici S.p.A. as the company focuses on higher-return businesses. Shares of the company have underperformed the industry. With the company’s efforts to expand Actimmune’s label suffered a setback, focus will be on Krystexxa’s performance. Stiff competition for drugs will also impact sales." (8/11/2017)
  • 3. Piper Jaffray Companies analysts commented, "We had the opportunity to travel with Horizon senior management in meetings with investors. We gained additional insight into Pennsaid 2% and Ravicti, and also came away with insights into management's latest thinking regarding M&A. Though there are undoubtedly some headwinds facing the primary care segment, we believe that this segment should be on largely stable footing over the long-term given HZNP's payer contracting efforts. That dynamic combined with continued strength from the rare disease segment points to a long-term EPS CAGR (2017-2022) in the mid-teens, and should translate into multiple expansion with a 2017E P/E currently at 7x. We reiterate our Overweight rating and are lowering our PT to $30 from $32 (see below for more details)." (3/24/2017)
  • 4. Guggenheim analysts commented, "HZNP reported a 4Q16 beat, underscoring our confidence that HZNP can continue to meet or exceed earnings expectations in '17+. Post 4Q16, we think that the peak sales potential of Pennsaid 2%, Procysbi, and Krystexxa are underappreciated, with additional earnings upside potentially coming from M&A as HZNP redeploys cash generated by its Primary Care ("PC") business into business development focused on orphan and rare disease indication medicines. While concerns remain over growth prospects for HZNP's PC business, Ravicti and Actimmune, these assets continue to generate meaningful cash to fuel HZNP's growth aspiration of $2B in sales by 2020." (2/27/2017)
  • 5. Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)

Are investors shorting Horizon Pharma PLC?

Horizon Pharma PLC saw a drop in short interest in August. As of August 31st, there was short interest totalling 19,875,636 shares, a drop of 6.6% from the August 15th total of 21,291,050 shares. Based on an average daily trading volume, of 3,273,655 shares, the short-interest ratio is currently 6.1 days. Currently, 12.3% of the shares of the stock are short sold.

Who are some of Horizon Pharma PLC's key competitors?

Who are Horizon Pharma PLC's key executives?

Horizon Pharma PLC's management team includes the folowing people:

  • Timothy P. Walbert, Chairman of the Board, President, Chief Executive Officer
  • Paul W. Hoelscher, Chief Financial Officer, Executive Vice President
  • Barry J. Moze, Executive Vice President, Chief Administrative Officer
  • Brian K. Beeler, Executive Vice President, General Counsel
  • Robert F. Carey, Executive Vice President, Chief Business Officer
  • Michael A. DesJardin, Executive Vice President - Technical Operations
  • George P. Hampton, Executive Vice President - Primary Care Business Unit
  • David A. Happel, Executive Vice President - Orphan Business Unit
  • Jeffrey W. Sherman M.D., Executive Vice President - Research and Development and Chief Medical Officer
  • Vikram Karnani, Senior Vice President - Rheumatology Business Unit

Who owns Horizon Pharma PLC stock?

Horizon Pharma PLC's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.30%), Vanguard Group Inc. (7.98%), Dimensional Fund Advisors LP (3.85%), Paulson & CO. Inc. (3.02%), State Street Corp (3.00%) and Brandywine Global Investment Management LLC (2.42%). Company insiders that own Horizon Pharma PLC stock include Jeffrey W Sherman, Michael G Grey, Robert Carey and Virinder Nohria. View Institutional Ownership Trends for Horizon Pharma PLC.

Who sold Horizon Pharma PLC stock? Who is selling Horizon Pharma PLC stock?

Horizon Pharma PLC's stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., JPMorgan Chase & Co., Hodges Capital Management Inc., Farallon Capital Management LLC, FMR LLC, Fiera Capital Corp, Cornerstone Capital Management Holdings LLC. and Voya Investment Management LLC. View Insider Buying and Selling for Horizon Pharma PLC.

Who bought Horizon Pharma PLC stock? Who is buying Horizon Pharma PLC stock?

Horizon Pharma PLC's stock was purchased by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Dimensional Fund Advisors LP, William Blair Investment Management LLC, Balyasny Asset Management LLC, Neuberger Berman Group LLC, State Street Corp, Brandywine Global Investment Management LLC and Ameriprise Financial Inc.. View Insider Buying and Selling for Horizon Pharma PLC.

How do I buy Horizon Pharma PLC stock?

Shares of Horizon Pharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Horizon Pharma PLC's stock price today?

One share of Horizon Pharma PLC stock can currently be purchased for approximately $12.32.


MarketBeat Community Rating for Horizon Pharma PLC (NASDAQ HZNP)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  503 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  683
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Horizon Pharma PLC (NASDAQ:HZNP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $18.91 (53.48% upside)

Analysts' Ratings History for Horizon Pharma PLC (NASDAQ:HZNP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017Cantor FitzgeraldReiterated RatingBuy$17.00HighView Rating Details
9/10/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00LowView Rating Details
8/28/2017MizuhoReiterated RatingHold$9.00 -> $12.00MediumView Rating Details
8/10/2017BMO Capital MarketsReiterated RatingOutperform$17.00 -> $18.00HighView Rating Details
7/14/2017Jefferies Group LLCReiterated RatingBuy$14.00LowView Rating Details
5/9/2017Citigroup Inc.Lower Price TargetBuy$20.00 -> $13.00MediumView Rating Details
5/9/2017Stifel NicolausReiterated RatingBuy -> Buy$35.00 -> $20.00HighView Rating Details
5/9/2017Cowen and CompanySet Price TargetOutperform$42.00 -> $20.00MediumView Rating Details
2/28/2017Morgan StanleyReiterated RatingEqual Weight$20.00N/AView Rating Details
2/27/2017GuggenheimInitiated CoverageBuy$30.00N/AView Rating Details
10/12/2016Goldman Sachs Group, Inc. (The)Set Price TargetBuy$26.00N/AView Rating Details
9/12/2016Brean CapitalReiterated RatingBuy$32.00N/AView Rating Details
11/11/2015WallachBeth CapitalUpgradeBuyN/AView Rating Details
10/22/2015JMP SecuritiesReiterated RatingBuyN/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Horizon Pharma PLC (NASDAQ:HZNP)
Earnings by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Earnings History by Quarter for Horizon Pharma PLC (NASDAQ HZNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/16/2017$0.22N/AView Earnings Details
8/7/2017Q2 2017$0.12$0.41$237.01 million$289.51 millionViewListenView Earnings Details
5/8/2017Q1 2017$0.25$0.21$248.71 million$220.90 millionViewListenView Earnings Details
2/27/2017Q416$0.51$0.64$307.93 million$310.30 millionViewListenView Earnings Details
11/7/2016Q316$0.63$0.70$270.04 million$273.70 millionViewListenView Earnings Details
8/8/2016Q216$0.50$0.62$235.43 million$257.40 millionViewN/AView Earnings Details
5/9/2016Q116$0.30$0.34$197.73 million$204.70 millionViewN/AView Earnings Details
2/29/2016Q415$0.62$0.63$240.92 million$244.50 millionViewListenView Earnings Details
11/6/2015Q315$0.41$0.59$185.70 million$292.70 millionViewListenView Earnings Details
8/7/2015Q215$0.32$0.39$156.41 million$172.80 millionViewListenView Earnings Details
5/8/2015Q115$0.22$0.16$104.20 million$113.10 millionViewN/AView Earnings Details
2/27/2015Q414$0.23$0.27$95.50 million$103.80 millionViewN/AView Earnings Details
11/6/2014Q314$0.19$0.24$73.17 million$75.10 millionViewN/AView Earnings Details
8/7/2014Q214$0.16$0.14$58.35 million$66.10 millionViewN/AView Earnings Details
5/9/2014Q114$0.01$0.10$42.69 million$51.90 millionViewN/AView Earnings Details
3/13/2014Q413($0.08)($0.22)$32.20 million$43.10 millionViewN/AView Earnings Details
11/8/2013Q3 13($0.25)($0.03)$18.31 million$31.50 millionViewN/AView Earnings Details
8/9/2013Q213($0.32)($0.24)$16.09 million$17.64 millionViewN/AView Earnings Details
5/10/2013Q113($0.35)($0.30)$9.47 million$9.20 millionViewN/AView Earnings Details
11/13/2012Q312($0.68)($0.39)$4.12 million$7.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Horizon Pharma PLC (NASDAQ:HZNP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171$0.10$0.10$0.10
Q3 20171$0.19$0.19$0.19
Q4 20171$0.17$0.17$0.17
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Horizon Pharma PLC (NASDAQ:HZNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Horizon Pharma PLC (NASDAQ:HZNP)
Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 82.30%
Insider Trades by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Insider Trades by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2017Michael G GreyDirectorBuy10,000$9.48$94,800.00View SEC Filing  
3/1/2017Robert CareyEVPSell31,808$16.03$509,882.24View SEC Filing  
8/2/2016Jeffrey W. ShermanEVPSell2,900$20.00$58,000.00View SEC Filing  
6/15/2016Virinder NohriaDirectorSell25,000$17.69$442,250.00View SEC Filing  
2/26/2016Jeffrey W ShermanEVPSell4,100$20.00$82,000.00View SEC Filing  
12/10/2015Jeffrey W ShermanEVPSell4,456$20.00$89,120.00View SEC Filing  
9/21/2015Jeffrey W ShermanEVPSell7,750$31.78$246,295.00View SEC Filing  
7/15/2015Jeffrey W ShermanEVPSell26,887$35.55$955,832.85View SEC Filing  
3/13/2015Jeff HimawanDirectorSell554,564$22.44$12,444,416.16View SEC Filing  
3/10/2015Jeff HimawanDirectorSell1,614,827$21.85$35,283,969.95View SEC Filing  
11/19/2014Jeff HimawanDirectorSell3,450,000$12.05$41,572,500.00View SEC Filing  
11/19/2014Jeffrey W ShermanEVPSell24,999$12.05$301,237.95View SEC Filing  
11/19/2014Timothy P WalbertCEOSell150,000$12.05$1,807,500.00View SEC Filing  
11/13/2014Balaji VenkataramanMajor ShareholderSell6,086,957$11.54$70,243,483.78View SEC Filing  
11/13/2014Virinder NohriaDirectorSell1,739,130$11.54$20,069,560.20View SEC Filing  
9/30/2014Vaere Robert J DeCFOSell51,942$12.28$637,847.76View SEC Filing  
5/19/2014Timothy WalbertCEOSell31,742$12.94$410,741.48View SEC Filing  
5/19/2014Todd SmithEVPSell10,159$12.94$131,457.46View SEC Filing  
5/19/2014Vaere Robert DeCFOSell12,939$12.94$167,430.66View SEC Filing  
12/13/2013Jeffrey BirdDirectorBuy668,673$6.50$4,346,374.50View SEC Filing  
12/9/2013Timothy WalbertCEOSell12,124$6.79$82,321.96View SEC Filing  
12/9/2013Todd SmithEVPSell11,322$6.91$78,235.02View SEC Filing  
11/21/2013Jeffrey BirdDirectorBuy151,089$6.24$942,795.36View SEC Filing  
9/25/2012Jeffrey W BirdDirectorBuy575,356$3.49$2,007,992.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Horizon Pharma PLC (NASDAQ:HZNP)
Latest Headlines for Horizon Pharma PLC (NASDAQ:HZNP)
Source:
DateHeadline
finance.yahoo.com logoIs Horizon Pharma (HZNP) A Suitable Pick for Value Investors?
finance.yahoo.com - September 22 at 2:16 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Expected to Post Quarterly Sales of $254.14 Million
www.americanbankingnews.com - September 18 at 8:56 AM
americanbankingnews.com logoFY2018 Earnings Forecast for Horizon Pharma PLC (HZNP) Issued By Cantor Fitzgerald
www.americanbankingnews.com - September 18 at 6:26 AM
reuters.com logoHorizon Pharma weighs sale of primary care unit -sources - Reuters
www.reuters.com - September 16 at 6:54 PM
seekingalpha.com logoHorizon Pharma mulling sale of primary care drugs unit; shares ease 2%
seekingalpha.com - September 15 at 7:22 PM
americanbankingnews.com logoShort Interest in Horizon Pharma PLC (HZNP) Declines By 6.6%
www.americanbankingnews.com - September 15 at 1:02 AM
finance.yahoo.com logoHorizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : September 14, 2017
finance.yahoo.com - September 14 at 11:05 PM
finance.yahoo.com logoETFs with exposure to Horizon Pharma Plc : September 13, 2017
finance.yahoo.com - September 14 at 6:15 AM
globenewswire.com logoHorizon Pharma plc Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer - GlobeNewswire (press release)
globenewswire.com - September 12 at 1:09 AM
americanbankingnews.com logoPiper Jaffray Companies Analysts Give Horizon Pharma PLC (HZNP) a $18.00 Price Target
www.americanbankingnews.com - September 11 at 8:24 PM
finance.yahoo.com logoHorizon Pharma plc Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer
finance.yahoo.com - September 11 at 8:08 PM
finance.yahoo.com logoHorizon Pharma Plc :HZNP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
finance.yahoo.com - September 11 at 8:08 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Given "Buy" Rating at Cantor Fitzgerald
www.americanbankingnews.com - September 11 at 5:18 PM
americanbankingnews.com logoComparing Horizon Pharma PLC (HZNP) & its Peers
www.americanbankingnews.com - September 11 at 8:36 AM
finance.yahoo.com logoHorizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - September 6 at 6:13 AM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Lowered to Hold at ValuEngine
www.americanbankingnews.com - September 3 at 9:06 AM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Expected to Announce Quarterly Sales of $254.14 Million
www.americanbankingnews.com - August 31 at 11:36 AM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Given Neutral Rating at Mizuho
www.americanbankingnews.com - August 28 at 9:36 AM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Sees Large Growth in Short Interest
www.americanbankingnews.com - August 26 at 1:20 AM
finance.yahoo.com logoHorizon Pharma plc to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - August 25 at 6:55 AM
finance.yahoo.com logoNuvo Pharmaceuticals™ Secures Credit Facility from the Royal Bank of Canada
finance.yahoo.com - August 24 at 7:43 AM
finance.yahoo.com logoHorizon Pharma Plc – Value Analysis (NASDAQ:HZNP) : August 21, 2017
finance.yahoo.com - August 22 at 8:06 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) & Cambrex Corporation (CBM) Head to Head Comparison
www.americanbankingnews.com - August 19 at 10:22 PM
finance.yahoo.com logoHere's Why Horizon Pharma Gained as Much as 13.1% Today
finance.yahoo.com - August 18 at 4:57 AM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Given a $17.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - August 17 at 6:22 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Horizon Pharma PLC.
finance.yahoo.com - August 16 at 7:40 PM
americanbankingnews.com logoZacks: Brokerages Expect Horizon Pharma PLC (NASDAQ:HZNP) Will Post Quarterly Sales of $254.14 Million
www.americanbankingnews.com - August 12 at 6:50 AM
finance.yahoo.com logoIHS Markit Score upgrades Horizon Pharma PLC to 40 out of 100, despite ranking positively in only one IHS Markit category.
finance.yahoo.com - August 11 at 8:08 PM
americanbankingnews.com logoHorizon Pharma PLC (NASDAQ:HZNP) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 11 at 2:14 PM
americanbankingnews.com logoFY2017 Earnings Estimate for Horizon Pharma PLC (HZNP) Issued By Jefferies Group
www.americanbankingnews.com - August 11 at 12:02 PM
finance.yahoo.com logoIHS Markit Score downgrades Horizon Pharma PLC to 30 out of 100, ranking positively in only one out of three available IHS Markit categories.
finance.yahoo.com - August 11 at 3:10 AM
finance.yahoo.com logoHorizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : August 10, 2017
finance.yahoo.com - August 11 at 3:10 AM
americanbankingnews.com logoCantor Fitzgerald Analysts Boost Earnings Estimates for Horizon Pharma PLC (NASDAQ:HZNP)
www.americanbankingnews.com - August 10 at 1:40 PM
americanbankingnews.com logoHorizon Pharma PLC to Post Q3 2017 Earnings of $0.19 Per Share, Jefferies Group Forecasts (NASDAQ:HZNP)
www.americanbankingnews.com - August 10 at 7:06 AM
americanbankingnews.com logoHorizon Pharma PLC's (HZNP) Overweight Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - August 9 at 10:58 PM
finance.yahoo.com logoNuvo Pharmaceuticals™ Announces 2017 Second Quarter Results
finance.yahoo.com - August 9 at 7:54 PM
finance.yahoo.com logoHorizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View
finance.yahoo.com - August 8 at 7:22 PM
americanbankingnews.com logoHorizon Pharma PLC (NASDAQ:HZNP) Given a $16.00 Price Target by UBS AG Analysts
www.americanbankingnews.com - August 8 at 10:06 AM
247wallst.com logoHorizon Pharma Wins Big in Q2 - 24/7 Wall St.
247wallst.com - August 8 at 5:12 AM
finance.yahoo.com logoEdited Transcript of HZNP earnings conference call or presentation 7-Aug-17 12:00pm GMT
finance.yahoo.com - August 8 at 12:10 AM
marketwatch.com logoHorizon Pharma shares surge 19% on Q2 profit, revenue beats and upbeat guidance
www.marketwatch.com - August 7 at 7:10 PM
seekingalpha.com logoHorizon Pharma Plc (HZNP) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 7:10 PM
finance.yahoo.com logoHorizon Pharma (HZNP) Tops Earnings in Q2, Shares Up
finance.yahoo.com - August 7 at 7:10 PM
finance.yahoo.com logoMorning Movers: Tyson Jumps, Horizon Soars, Teva Tumbles
finance.yahoo.com - August 7 at 7:10 PM
finance.yahoo.com logoBiotech Movers: Second Quarter Results, Increased Outlook Send Horizon Pharma Shares Higher
finance.yahoo.com - August 7 at 7:10 PM
finance.yahoo.com logoHorizon Pharma reports 2Q loss
finance.yahoo.com - August 7 at 7:10 PM
americanbankingnews.com logoHorizon Pharma PLC (NASDAQ:HZNP) Given a $18.00 Price Target by Piper Jaffray Companies Analysts
www.americanbankingnews.com - August 7 at 6:20 PM
investorplace.com logoHorizon Pharma PLC (HZNP) Q2 Report Sends Shares Surging
investorplace.com - August 7 at 11:56 AM
fool.com logoWhy Horizon Pharma plc Stock Is Rising Today
www.fool.com - August 7 at 9:55 AM
americanbankingnews.com logoHorizon Pharma PLC (NASDAQ:HZNP) Issues Earnings Results, Beats Estimates By $0.29 EPS
www.americanbankingnews.com - August 7 at 8:50 AM

Social

Chart

Horizon Pharma PLC (HZNP) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff